Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis by Mammana, Santa et al.
Oncotarget8263www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/                      Oncotarget, 2018, Vol. 9, (No. 9), pp: 8263-8277
Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal 
models of multiple sclerosis 
Santa Mammana1, Placido Bramanti2, Emanuela Mazzon2, Eugenio Cavalli1, Maria 
Sofia Basile1, Paolo Fagone1, Maria Cristina Petralia3, James Andrew McCubrey4, 
Ferdinando Nicoletti1 and Katia Mangano1
1Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
2IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy
3Department of Educational Sciences, University of Catania, Catania, Italy
4Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA
Correspondence to: Paolo Fagone, email: paolofagone@yahoo.it
Keywords: multiple sclerosis; mTOR; autoimmunity; bioinformatics
Received: September 12, 2017    Accepted: November 13, 2017    Published: January 03, 2018
Copyright: Mammana et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC 
BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that 
regulates cell activation. proliferation, metabolism and apoptosis. Increasing body 
of data suggests that alterations in the PI3K/AKT/mTOR pathway may result in an 
enhanced susceptibility to autoimmunity. Multiple Sclerosis (MS) is one of the most 
common chronic inflammatory diseases of the central nervous system leading to 
demyelination and neurodegeneration. 
In the current study, we have firstly evaluated in silico the involvement of the 
mTOR network on the generation and progression of MS and on oligodendrocyte 
function, making use of currently available whole-genome transcriptomic data. Then, 
the data generated in silico were subjected to an ex-vivo evaluation. To this aim, the 
involvement of mTOR was validated on a well-known animal model of MS and in vitro 
on Th17 cells.
Our data indicate that there is a significant involvement of the mTOR network 
in the etiopathogenesis of MS and that Rapamycin treatment may represent a useful 
therapeutic approach in this clinical setting. On the other hand, our data showed 
that a significant involvement of the mTOR network could be observed only in the 
early phases of oligodendrocyte maturation, but not in the maturation process of 
adult oligodendrocytes and in the process of remyelination following demyelinating 
injury.
Overall, our study suggests that targeting the PI3K/mTOR pathway, although it 
may not be a useful therapeutic approach to promote remyelination in MS patients, 
it can be exploited to exert immunomodulation, preventing/delaying relapses, and 
to treat MS patients in order to slow down the progression of disability.
INTRODUCTION
Multiple Sclerosis (MS) is one of the most common 
chronic inflammatory diseases of the central nervous 
system leading to demyelination and neurodegeneration.
The PI3K/Akt/mTOR signalling pathway is 
strictly involved in T cell responses. Both mTORC1 
and mTORC2 are activated within minutes after TCR 
stimulation and the magnitude of mTOR activation 
is directly correlated with the duration of interaction 
between T cells and dendritic cells. Increasing body 
of data suggests that alterations in the PI3K/Akt/
mTOR pathway may result in enhanced susceptibility 
to autoimmunity [1, 2]. Beside regulating immune 
responses, the PI3K/Akt/mTOR has also been proven 
to be involved in several other functions including, 
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chemoresistance, aging and host response to viral 
infections [3–8].
Therefore, drugs targeting the PI3K/Akt/mTOR 
pathway are currently under extensive investigation for 
their possible use in different therapeutic settings, and 
they have been approved for the treatment of certain forms 
of cancer, prevention of allograft rejection, for tuberous 
sclerosis complex-associated renal angiomyolipoma and 
subependymal giant cell astrocytoma [9–12].
Of note, approval of PI3K/Akt/mTOR inhibitors for 
immunoinflammatory and autoimmune diseases is so far 
lacking, although large and independent clinical studies 
have shown clear-cut efficacy of rapamycin in patients 
with non-infectious posterior uveitis.
The identification of novel disease indications for 
approved drugs, a.k.a. drug repositioning, offers several 
advantages over traditional drug development [13]. 
Indeed, drug discovery is generally protracted and costly, 
taking on average approximately 15 years and over $1 
billion to develop and bring a novel drug to the market 
[14]. A large part of drug development costs are employed 
during early development and toxicity testing, with more 
than 90% of drugs failing to move beyond these early 
stages [15]. The repositioning of drugs already approved 
for human use cuts the costs and risks associated with 
early stages of drug development, and offers shorter paths 
to approval for novel therapeutic indications.
Preclinical and clinical studies anticipating a 
beneficial role for mTOR inhibitors in patients with 
multiple sclerosis [16] have prompted us to evaluate the 
potential use of Rapamycin in the context of MS. The 
study followed a multi-tier approach, based on in silico, 
in vitro and ex vivo analysis. The first in silico approach 
was aimed at evaluating the involvement of the mTOR 
network on the generation and progression of MS. Then, 
we evaluated whether genes modulated by Sirolimus 
were among those observed to be altered in the disease. 
The hypothesis underlying this approach is that if a drug 
affects the expression of genes oppositely modulated in 
a disease, that drug has the potential to be used for the 
treatment of that disease. 
Next, we wanted to evaluated the involvement of 
the mTOR network on oligondendrocyte function, in 
order to ascertain whether treatment with drugs targeting 
the PI3K/Akt/mTOR pathway may be useful to promote 
the remyelination process, so to reverse disability in MS 
patients.
Finally, the data generated in silico were subjected 
to an ex-vivo evaluation. To this aims the involvement of 
mTOR was validated first on a well-known and established 
animal model of MS in the mouse, the MOG-induced 
EAE model. Finally, given the role of Th17 cells in the 
pathogenesis of EAE/MS, we determined whether mTORC1 
inhibition via Rapamycin treatment on CD4 T cells upon 
Th17 conditions, was able to modulate the expression levels 
of the genes previously identified in the in silico analysis.
MATERIALS AND METHODS
In silico analysis
Generation of the MS “Disease gene signature” and of 
Rapamycin “Drug regulated genes”
Expression datasets for disease and drug effects 
were obtained from the NCBI Gene Expression Omnibus 
(GEO, http://www.ncbi.nlm.nih.gov/geo/). MESH terms 
“Multiple Sclerosis” and “Rapamycin” were used to 
identify potential datasets of interest and GSE29606 and 
GSE38645 were chosen for the analysis. The GEO2R web 
application was used to identify differentially expressed 
genes. In cases where multiple microarray probes mapped 
to the same NCBI GeneID, we chose the probes which 
showed the maximum variance. On each data set, we 
performed moderate t statistics to generate a list of up-
regulated and down-regulated genes. We used a threshold 
of p < 0.05 and fold change > 1.5. The list of significantly 
up and down regulated genes for each comparison were 
considered for further analysis.
Generation of the mTOR “Regulatory molecular 
network”
Highly complex phenotypes arise from a relatively 
restricted set of gene families connected by a tightly 
regulated network of interactions. The STRING database 
(http://string-db.org/) allows to have access to a global 
view of all the available interaction data by creating large 
networks, which captures the current knowledge on the 
functional modularity and interconnectivity of genes in a 
cell. The majority of associations generated with STRING 
derives from predictions which are based on analyzing 
genomic information or from transferring associations/
interactions among organisms. All associations are 
provided with a confidence score that represents a rough 
estimate of how likely a given association describes a 
functional linkage between two proteins. For the current 
study, the search term “MTOR” was used to generate a 
network, using a confidence score of 0.7 and by including 
no more than 20 interactors per gene. 
Dataset selection and analysis of oligodendrocyte 
damage and remyelination processes
Expression datasets were obtained from NCBI 
Gene Expression Omnibus (GEO, http://www.ncbi.
nlm.nih.gov/geo/). GSE32645 and GSE48872 were 
chosen for the analysis. From GSE32645, we selected 
the three active MS lesions samples (one fulminant 
active lesion and two chronic active lesions), and the 
three cortex samples from controls without brain 
pathology. Complete demographic data of patients and 
controls can be obtained from the relative publication 
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[17]. GSE48872 included gene expression profiles 
from neonatal oligodendrocyte precursors (nOPCs) and 
adult OPCs isolated from the brain of postnatal (day 
1 to day 5) and 2-month-old mice, while adult OPCs 
in demyelinating conditions (activated aOPCs) were 
isolated from the brain of mice previously treated for 
5 weeks with cuprizone (0.2%). Adult oligodendrocytes 
(OLs) were obtained from brains of 2-month-old mice 
[18]. The GEO2R web application was used to identify 
differentially expressed genes. In cases where multiple 
microarray probes mapped to the same NCBI GeneID, 
we chose the probes which showed the lowest p value. 
On each data set, we performed a Student’s T test to 
generate a list of up-regulated and down-regulated 
genes. We used a threshold of p < 0.05 and fold change 
> 2. The list of significantly up and down regulated 
genes for each comparison were considered for the gene 
enrichment analysis using the Chi-square test with Yates’ 
correction using the mTOR pathway as background. A p 
value  < 0.05 was considered to be statistical significant. 
Gene enrichment analysis
In order to evaluate the significance of gene-term 
enrichment using the mTOR “Regulatory Molecular 
Network” or the Rapamycin “Drug regulated genes” as 
background, a Chi-square test with Yates’ correction was 
performed for the selected genes. A p value  < 0.05 was 
considered to be statistical significant. 
Ex vivo and in vitro analysis
 Animals
Eight to 10 weeks old female C57BL⁄6 mice 
will be purchased from ENVIGO RMS srl (San Pietro 
al Natisone, Udine, Italy). The animals were kept at 
the animal facility of the Department of Biomedical 
and Biotechnological Sciences, Section of General 
Pathology, Catania, Italy. They were kept under standard 
laboratory conditions (non-specific pathogen-free) 
with free access to food (Harlan Global Diet 2018) 
and water and were allowed to adapt at least one week 
to their environment before commencing the study. 
Automatically controlled environmental conditions were 
set to maintain temperature at 20 – 24°C with a relative 
humidity (RH) of 30 – 70% ,10-30 air changes /hr and 
a natural dark:light cycle. Protection of animals used in 
the experiment is in accordance with Directive 86/609/
EEC, enforced by the Italian D. Lgs 26/2014.
Induction of MOG-induced EAE in C57BL⁄ 6 
mice
MOG 35-55 was synthetized by Genemed synthesis 
(San Francisco CA). The mice were immunized with 200 
ug  MOG emulsified in CFA with 1 mg of Mycobacterium 
tuberculosis H37RA (Difco, Detroit, MI, USA) to make 
a 1:1 emulsion. Each mouse received subcutaneous 
injections of 200 ml emulsion divided among two sites 
draining into the axillary lymphnodes. Pertussis toxin 
(Calbiochem, Nottingham, UK) was used as a co-adjuvant 
and was administered i.p. at the dose of 200 ng/mouse on 
day 0 and 2 post immunization. The mice were observed 
every day by measuring their body weights and clinical 
signs of EAE. The clinical grading were carried out by 
an observer unaware of the treatment: 0 = no sign of 
disease; 0.5 = partial tail paralysis; 1 = tail paralysis; 1.5 
= tail paralysis + partial unilateral hindlimb paralysis; 2 
= tail paralysis + hindlimb weakness or partial hindlimb 
paralysis; 2.5 = tail paralysis + partial hindlimb paralysis 
(lowered pelvi); 3 = tail paralysis + complete hindlimb 
paralysis; 3.5 = tail paralysis + complete hindlimb 
paralysis + incontinence; 4 = tail paralysis + hindlimb 
paralysis + weakness or partial paralysis of forelimbs; 5 
= moribund or dead.
Ex vivo restimulation with MOG 35-55
At the 14th day after EAE induction, spleens were 
harvested from C57BL/6 mice. Cell suspensions were 
prepared by grinding the organs with the plunger of a 
5 ml disposable syringe and suspending them in RPMI 
1640 medium supplemented with 10% fetal calf serum, 2 
mM glutamine, and 50 mg/ml of penicillin/streptomycin 
(complete medium). Splenocytes were treated with an 
ACK Lysis Buffer (Invitrogen, Monza, Italy) to remove 
red blood cells. Cells were pelleted and washed twice 
with PBS. Cells were resuspended at 2 × 106 cells/mL 
in complete medium and re-restimulated with 40 µg/mL 
of MOG or Concanavalin A (ConA; 10 μg/ml, Sigma 
Aldrich St. Louis MO, USA), and treated with increasing 
concentrations of BEZ-235, PX-866 and Rapamycin. 
Stock solutions were prepared in 100% dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich). Subsequent 
dilutions and controls were prepared to account for the 
inclusion of DMSO in the stock solution. The effect of 
test compounds on MOF-induced cell proliferation was 
measured using a BrdU (bromodeoxyuridine) assay 
kit (Calbiochem). The assay was performed as per the 
manufacturer›s protocol and proliferation was detected 
using a spectrophotometric measurement of absorbance 
at 450 nm.
Supernatant TNF-alpha levels 
For cytokine assays, harvested cells were plated in 
triplicate in 24-well microtiter plates at a concentration of 
2 × 106 cells/well, in the same medium, stimulated with 
MOG 35-55 (40 μg/ml) and incubated for 48h. At the end of 
the incubation period, supernatants were also collected for 
subsequent determination of TNF-alpha by ELISA (R&D 
systems, Minneapolis, MN, USA).
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In vitro effects of Rapamycin
Murine CD4+ CD25- T cells were magnetically 
isolated from wild-type mice. Cells were activated by 
adding 0.3 mg/mL hamster-anti-mouse CD3 and 0.5 mg/
mL hamster-CD28 antibodies to cells in wells pre-coated 
with 0.3 mg/mL goat-anti-hamster IgG. Th17-polarization 
was induced using 3 ng/mL recombinant human TGF-β1 
and 30 ng/mL recombinant mouse IL-6. 10 nM rapamycin, 
or vehicle control (DMSO) were added to cultures at the 
time of activation. Cells were harvested at 18 and 72 hours 
post-activation and RNA isolated from each sample for 
subsequent qRT-PCR analysis. 
Total RNA was extracted using Trizol reagent 
(Invitrogen, Monza, Italy) according to the manufacturer’s 
protocol. Reverse transcription reactions were performed 
using retro-transcription reagents from Roche. Real-time 
PCR analyses were carried out using primers in house 
designed or downloaded from PrimerBank (https://pga.
mgh.harvard.edu/primerbank/).
Statistical analysis
Data are shown as Mean±S.D. of at least three 
biological replicates, each one being performed as 
technical triplicate. Statistical analysis was performed 
using either the Student’s T test or Mann-Whitney U 
test based on the results obtained from the Shapiro-
Wilk and Kolmogorov-Smirnov Normality Test. The 
GraphPad Prism was used for the statistical analysis and 
the generation of the graphs. Fisher’s Inverse χ2 test was 
used as integrative analysis for rapamycin effects on Th17 
cells. It computes a combined statistic from the P-values 
obtained from the individual datasets, 
which follows a χ2 distribution with 2/degrees of 
freedom under the null hypothesis.
RESULTS
Generation of the mTOR network
The mTOR network generated by STRING included 
318 unique genes (Figure 1). Gene Ontology (GO) analysis 
identified as the top 3 Molecular Functions: binding 
activity (GO:0005488); catalytic activity (GO:0003824); 
and nucleic acid binding transcription factor activity 
(GO:0001071). Binding activity (GO:0005488) included: 
protein binding (GO:0005515)(51.10% of the genes); 
nucleic acid binding (GO:0003676) (34.50% of the 
genes); calcium ion binding  (GO:0005509)(6.90% of 
the genes); calcium-dependent phospholipid binding 
(GO:0005544) (5.70% of the genes); and chromatin 
binding (GO:0003682) (1.70% of the genes) (Figure 2). 
Catalytic activity (GO:0003824) included: 
transferase activity (GO:0016740) (39.00% of the genes); 
hydrolase activity (GO:0016787) (29.90% of the genes); 
enzyme regulator activity (GO:0030234) (17.10% of 
the genes); ligase activity (GO:0016874) (5.50% of the 
genes); oxidoreductase activity (GO:0016491) (3.70% of 
the genes); isomerase activity (GO:0016853) (3.70% of 
the genes); and lyase activity (GO:0016829) (1.20% of the 
genes (Figure 2)).
Among the top enriched Biological Processes, we 
found: cellular process (GO:0009987); metabolic process 
(GO:0008152); and biological regulation (GO:0065007), 
followed by response to stimulus (GO:0050896); 
developmental process (GO:0032502); cellular component 
organization or biogenesis (GO:0071840); immune 
system process (GO:0002376); multicellular organismal 
process (GO:0032501); apoptotic process (GO:0006915); 
localization (GO:0051179) and biological adhesion 
(GO:0022610) (Figure 2).
The most represented Protein Classes in the 
mTOR network were: nucleic acid binding (PC00171) 
proteins, transferases (PC00220), kinases (PC00137), 
enzyme modulators (PC00095) and transcription 
factors (PC00218). Less represented protein classes 
were: signaling molecules (PC00207), calcium-binding 
proteins (PC00060), hydrolases (PC00121), chaperones 
(PC00072), transfer/carrier proteins (PC00219), 
cytoskeletal proteins (PC000085) and phosphatases 
(PC00181) (Figure 2).
Involvement of the mTOR network in MS
The mTOR network was used for comparison with 
the upregulated genes involved in MS development as 
obtained from GSE38645. For the latter, total RNA was 
extracted from sorted ex vitro myelin specific CD4+T 
cells (activated phenotype) or isolated from the spleen 
(migratory phenotype). Myelin specific activated and 
migratory CD4+ T cells were defined by 873 and 366 
up-regulated genes, respectively, with 172 genes being 
shared between the two groups (Figure 7; Table 1). When 
comparing these genes with those belonging to the mTOR 
pathway, we found that 28 were in common with the 
activated phenotype and 12 with the migratory phenotype. 
Chi square test revealed a strong significant enrichment (p 
< 0.0001) in both cases. 7 genes shared among the mTOR 
network, the CD4 Activated and the CD4 Migratory 
Phenotypes (Figure 3). 
Rapamycin effects in MS
Differential expressed genes in CD4+ T cells upon 
Rapamycin treatment were derived from the GSE29606 
dataset. 217 and 297 genes were found respectively 
downregulated and up-regulated by Rapamycin in anti-
CD3/CD28 stimulated CD4+CD25- T cells (Table 1).
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Rapamycin was associated to the downregulation of 
12 (p = 0.029) and 6 (p = 0.075) genes implicated in the 
activated and migratory phenotype, respectively (Table 1). 
No significant enrichment was observed for the genes up-
regulated by Rapamycin treatment (Table 1). 
Involvement of the mTOR pathway in MS 
cortical lesions 
Gene expression analysis of cortical MS lesion, 
revealed that 126 and 401 genes are significantly up- and 
down-regulated, respectively, as compared to control 
brains. Among these genes, 3 upregulated (p = 0.3334) and 
9 downregulated (p = 0.0486) genes resulted in common 
to the mTOR network (Table 2). The 3 upregulated genes 
included BAX, TERT and ERBB2. The 9 downregulated 
genes included JUN, ATF4, CASP3, CDKN1A, EIF4G1, 
PIK3R3, PML, STAT3, and YWHAZ. Gene Ontology 
analysis for the category “Biological Process” of the 9 
downregulated genes revealed that the top 3 enriched 
functions were Metabolic Process (GO:0008152) (24%), 
Biological Regulation (GO:0065007) (23%), Cellular 
Process (GO:0009987) (20%)  (Table 2).
Involvement of the mTOR pathway in 
oligodendrocyte function
First, we wanted to evaluate the involvement of 
the mTOR network in the developmental process of 
oligodendrocytes. To this aim, we analyzed the differential 
transcriptomic features of neonatal oligodendrocyte 
precursors (nOPCs) as compared to adult oligodendrocyte 
Table 1: Involvement of rapamycin in multiple sclerosis
Rapamycin
Downregulated 
genes (n = 217) 
vs.
Genes in common P Value
CD4 Activated 
Phenotype
Upregulated genes  
(n = 873)
AIMP1, CKDK, CENPM, KIF20A, LMNB1, MCM4, ME2, 




genes (n = 366)
KIF20A, LMNB1, MCM4, MKI67, S100A11, UHRF1 P = 0.0801
Common genes 








genes (n = 297) 
vs.




genes (n = 546)





genes (n = 245)
DBP, IGFLR1,VMP1 P = 0.9618
Common genes 




DBP, IGFLR1, VMP1 P = 0.1296
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precursors (aOPCs). We found that nOPCs are 
characterized by 2592 upregulated genes and 1714 
downregulated genes as compared to aOPCs. Among 
the hyperexpressed genes, 52 belonged to the mTOR 
network (p < 0.0001) while, among the downregulated 
genes, 27 were in common to the mTOR network (p = 
0.0716) (Table 2). Gene term enrichment analysis revealed 
that the 52 genes mainly belonged to the Cellular Process 
(GO:0009987) (24%), Metabolic Process (GO:0008152) 
(21%) and Biological Regulation (GO:0065007) (17%) 
categories (Table 2). 
When analyzing the involvement of the mTOR 
network in adult oligodendrocytes (OLs) development 
from aOPCs, we found that only 3 and 6 among the 
upregulated and downregulated genes, belonged to the 
mTOR network (p = 0.8512 and p = 0.6944, respectively) 
(Table 2).
Similarly, the activated aOPCs from cuprizone treated 
animals showed that among the upregulated and downregulated 
genes, only 15 and 12 genes belonged to the mTOR network 
(p = 0.5881 and p = 0.7915, respectively) (Table 2).
Effects of PI3K/mTOR inhibitors in MS
In order to validate the data previously obtained in 
the in silico analysis, we immunized C57Bl/6 mice with 
MOG35-55 and at overt disease, splenocytes were collected 
and re-stimulated with antigenic peptide in the presence 
of scalar concentrations of the mTORC1 inhibitor, 
Rapamycin, the PI3K inhibitor, PX-866,  and the dual 
mTOR/PI3K inhibitor, BEZ-235.
The concentrations tested were not toxic to cells, 
as evaluated upon  72 hours of exposure in healthy mice 
splenocytes (data not shown).
Table 2: Involvement of the mTOR network in oligodendrocyte function
mTOR network 
(n = 318) vs. Genes in common P Value
Cortical lesions
upregulated genes 













BCL2, BIRC5, CASP3, CCNB1, CCND1, CCND2, CCND3,
CCNE1, CDC25B, CDH1, CDH5, CDK1, CDK4, CDKN1A,
DMD, EGFR, EIF4EBP1, ERBB2, ESR1, ETS1, FLT1, FLT4,
FOS, FOXP2, GNB2L1, HES5, ID2, IGF1, IGF2, IGFBP1,
IGFBP3, IRS1, ITPR2, LPL, MAGED1, MAP3K8, MKNK2,
MYC, MYCN, NFATC4, PAX6, PDK1, PIK3R3, PPARGC1A,






BCL2L1, CALM1, CRTC2, DIS3L2, ERBB3, FBXO32, FLT3, 
HDAC9, JAK3, KDR, MAPK14, MAPK3, NFKB1, PDK2,
PIK3C3, PPARG, PRKCA, PRR5L, RAP1A, RHOB, 
RPS6KA1,













ATF4, BCL2, BDNF, CCND1, CDKN1A, EIF4EBP1, FOS,




BCL2L11, IL2, KDR, KIT, KRAS, MYCN, PIK3C3, PIK3CD,
RAP1A, RPS6KB1, RPS6KB2, RRAGB P = 0.7915
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Figure 1: mTOR regulatory molecular network (obtained in STRING  DB).
Figure 2: mTOR regulatory molecular network ontology (performed with PANTHER software).
Oncotarget8270www.impactjournals.com/oncotarget
Rapamycin was associated to a  ~40% reduction in 
MOG-specific proliferation in the dose range of 25-100 
nM (Figure 4). PX-866 was not effective in reducing the 
antigen-induced proliferation at concentration up to 100 
nM. A modest reduction of ~20% was observed at the 800 
nM concentration.
BEZ-235 exerted a dose-dependent reduction in 
MOG-specific proliferation, reaching a ~40% reduction 
at 100 nM. 
We also evaluated the ability of the test compounds 
to inhibit TNF-alpha production (Figure 4). Rapamycin 
significantly reduced the levels of TNF-alpha at all the 
concentrations in the range of 6.25-100 nM, as compared 
to control treated MOG-stimulated cells (Figure 4). A 
dose-dependent reduction in cytokine secretion was 
observed for PX-866 in the dose range of 25-800 nM. No 
significant reduction was detected for PX-866 at 25 nM 
concentration (Figure 4). BEZ-235 significantly reduced 
TNF-alpha levels at 50 and 100 nM concentrations. A 
reduction, although not significant was however observed 
also at 6.25–12.5-50 nM (Figure 4). 
Effects of mTORC1 inhibition on T cells under a 
Th17 polarizing condition
We wanted to evaluate whether mTORC1 inhibition 
was able to modulate the expression levels of the genes 
previously identified in the in silico analysis (Figure 
7B–7D).  Given the role of Th17 cells in the pathogenesis 
of EAE/MS [19], we stimulated murine T cells with anti-
CD3/ anti-CD28 antibodies, in the presence of TGF-beta 
and IL-6, and 10 nM Rapamycin were added to cultures. 
Gene expression analysis was performed via qRT-PCR at 
18 and 72 hours.
With the exception of BYSL, Rapamycin was able to 
significantly downregulate the expression of all the genes 
shared among the mTOR network, the CD4 Activated 
and the CD4 Migratory Phenotypes in CD4 T cells (a 
network showing the relationship among these genes is 
presented in Figure 7B) at 18h of incubation, entailing 
an overall strong statistical significance (p < 0.001 by 
Fisher Inverse Chi Square) (Figure 5). This effect was 
not observed after 72h of culture (Figure 5). As regards 
Figure 3: (A) Venn Diagram showing shared genes between the mTOR network and significantly upregulated genes in the GSE38645 
dataset; (B) Network constructed on the 7 genes shared among the mTOR network, the CD4 Activated and the CD4 Migratory Phenotypes; 
(C) Network constructed on the 21 genes shared among the mTOR network and the CD4 Activated Phenotype; (D) Network constructed 
on the 5 genes shared among the mTOR network and the CD4 Migratory Phenotype.
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the effect of Rapamycin on the expression levels of the 
5 genes shared among the mTOR network and the CD4 
Migratory Phenotype in  CD4 T cells (a network showing 
the relationship among these genes is presented in Figure 
6), a significant reduction was observed only for PLEK 
at 72h (Figure 6). A trend of reduction was observed at 
18h for SGK1, although a significant upregulation was 
detected after 72h. As regards, the 21 genes shared among 
the mTOR network and the CD4 Activated Phenotype in 
CD4 T cells (a network showing the relationship among 
these genes is presented in Figure 7), Rapamycin was able 
to significantly downregulate PA2G4, RUVBL1, CCNE2 
and DKC1 at 18h and  RUVBL2, YWHAE, EIF3C, 
FKBP3, EIF4G1, HSP90AA1, PPP2R4, CDKN1A, 
EIF2S1 and EIF4EBP1 (Figure 7).
DISCUSSION AND CONCLUSIONS
MS is one of the most common chronic 
inflammatory diseases of the central nervous system 
leading to demyelination and neurodegeneration, with 
more than 23 million affected peoples. Despite the efforts 
to understand its etiopathogenesis and to identify effective 
and tolerable treatment strategies,  the majority of patients 
develop, over the years, important disabilities. 
mTOR is a kinase that regulates translation 
in response to nutrients and growth factors by 
phosphorylating components of the protein synthesis 
machinery, including p70 S6K and eukaryotic initiation 
factor (eIF)-4E binding protein-1 (4EBP-1), allowing 
eIF-4E to be involved in the assembly of a translational 
initiation complex [3, 20–25]. mTOR is a key component 
of the two complexes mTORC1 and mTORC2 and it 
is at the cross-road of the PI3K/Akt pathway. Indeed, 
activation of PI3K activates Akt, which localizes in the 
plasma membrane and exerts a number of downstream 
effects, including activation of CREB, inhibition p27, 
localization of FOXO in the cytoplasm, activation 
PtdIns-3ps, and activation of mTOR. On the other hand, 
mTORC2 phosphorylates the serine/threonine protein 
kinase Akt/PKB at a serine residue S473 and serine 
residue S450. Phosphorylation of the serine promotes Akt 
phosphorylation at threonine T308 residue by PDK1 and 
leads to full Akt activation.
Drugs targeting the PI3K/Akt/mTOR  pathway 
are currently under extensive investigation for their 
possible use as cancer chemotherapeutics and as 
immunosuppressive agents, but only a limited number 
of clinical trials is ongoing for the evaluation of their 
efficacy in the context of immunological disorders. A 
few independent reports have already shown that the 
administration of the mTORC1 inhibitor, Rapamycin, is 
able to modulate the course of the disease in preclinical 
murine models of MS [26–28]. However the exact role of 
the mTOR pathway in the development and progression of 
MS has not yet deeply investigated.
In the current work, we have first undertaken an 
in silico study to evaluate the involvement of the mTOR 
network on the generation and progression of MS and on 
oligondendrocyte function, in order to ascertain whether 
treatment with drugs targeting the PI3K/Akt/mTOR 
pathway may be useful to affect disease course and to 
promote the remyelination process, so to reverse disability 
in MS patients. Next, we wanted to validate the obtained 
results, in vitro and ex vivo, using the MOG-induced EAE 
preclinical model of MS.
Figure 4: Effects of Rapamycin, BEZ-235 and PX-866 on MOG-specific proliferation and TNF-alpha secretion.
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Overall, our data indicate that there is a 
significant involvement of the mTOR network in the 
ethiopathogenesis of MS and that Rapamycin treatment 
may represent a useful therapeutic approach in the clinical 
setting. In particular, Rapamycin appears to be particular 
effective on activated encephalitogenic T cells rather than 
on migratory T cells, a data which suggests Rapamycin as 
a drug useful to treat relapses rather than to prevent them.
Despite the usefulness of this in silico approach, there 
are several drawbacks to bear in mind. First, the therapeutic 
efficacy of a drug is far more complex than a simple match 
of expression profiles. Drugs have to reach the appropriate 
tissue at the appropriate concentration in order to exert an 
effect, and the route and timing of administration should be 
careful chosen and sometimes, personalized to the patients, 
in order to limit undesired side effects. Moreover, compounds 
may exert different effects on different tissues and organs. 
On the other hand however, with this approach we could 
analyze both direct and indirect effects of a drug. Finally, we 
cannot make informed evaluation whether the drug may find 
application in all types of a complex disease, such as MS.
Ex vivo analysis showed that treatment of MOG-
specific T cells from EAE affected mice with the mTOR 
inhibitor, Rapamycin, and the dual PI3K/mTOR inhibitor, 
BEZ-235, was able to significantly reduce antigen-
specific proliferation, upon MOG restimulation. A much 
lower effect was on the contrary, observed for the PI3K 
inhibitor, PX-866, suggesting a secondary role of the 
PI3K pathway in the regulation of T cell proliferation in 
response to antigens. Unexpectedly however, all of the 
three compounds were able to strongly and significantly 
inhibit the production  of the pro-inflammatory cytokine, 
TNF-alpha, by MOG-restimulated splenocytes from EAE 
affected mice.
Figure 5: Effect of Rapamycin on expression levels of the genes shared among the mTOR network, the CD4 activated 
and the CD4 migratory phenotypes in CD4 T cells, as measured by qRT-PCR in Th17 cells. 
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It should be pointed out, that several independent 
reports have shown that the inhibition of mTOR is 
associated to a negative feedback loop to Akt. In 
particular, Wan and collaborators [29] have shown in 
Rh30 and RD cells that rapamycin-induced increase of 
Akt phosphorylation was dependent on PI3K. In fact, 
pretreatment of these cells with the PI3K inhibitor, 
LY294002, resulted in a reduction of rapamycin-induced 
increase of Akt activation. On the contrary, the MEK 
inhibitor,  U0126, did not affect the rapamycin-mediated 
phosphorilation of Akt
Although we have not specifically looked at the 
activation state of the PI3K/Akt axis following rapamycin 
treatment, we have observed that there is no substantial 
improvement in the antigen-specific proliferation and 
TNF alpha secretion when a dual PI3k/mTOR inhibitor 
was added to the cells as compared to the selective 
mTOR inhibitor, Rapamycin. We can speculate that the 
increased rapamycin-dependent Akt activation could 
promote the phosphorylation of the Forkhead box family of 
transcription factors, with their consequent retention in the 
cytoplasmic compartment and the downregulation of target 
genes, such as Kruppel-like Factor 2 (KLF2). KLF2 has 
been reported to control CD62L, C–C Chemokine Receptor 
7 (CCR7), and Sphingosine-1-Phosphate Receptor (S1P1R) 
expression, therefore regulating the homing of lymphocytes 
to secondary lymphoid tissues [30].
In addition, we show that Rapamycin treatment of 
murine T cell stimulated under Th17 conditions, is able 
to significantly inhibit the expression of some of the 
genes previously identified in the in silico analysis. Up 
to now, only 4 of the genes identified in silico have been 
associated to MS and neurodegeneration, namely BIRC5, 
SGK1, MAP3K8 and PLEK, and with the exception 
of MAP3K8, all of these resulted to be modulated by 
Rapamycin treatment. Moreover, several other genes 
identified to be shared among the mTOR network and 
the MS CD4 T cell (i.e.,  PA2G4, RUVBL1, CCNE2, 
DKC1, RUVBL2, YWHAE, EIF3C, FKBP3, EIF4G1, 
HSP90AA1, PPP2R4, CDKN1A, EIF2S1 and EIF4EBP1) 
resulted significantly downregulated by Rapamycin. These 
genes included translation factors (EIF4EBP1, EIF3C, 
EIF4G1 and EIF2S1); centromere-DNA binding factor 
(DKC1); nucleic acid binding factor (PA2G4); chaperones 
(YWHAE and HSP90AA1) and chaperone isomerase 
(FKBP3); and enzyme modulators (PPP2R4, CCNE2 and 
CDKN1A).
It is well established that the inhibition of the mTOR 
signaling is able to divert T cell polarization toward an 
immunoregulatory phenotype. Indeed, mTOR inhibition 
has been reported to induce the upregulation of FoxP3 
and to expand the population of nTregs. On the contrary, 
an increase in Akt phosphorylation, via deletion of 
PTEN, is associated to impaired Treg cell polarization. 
Mtor−/− T cells are characterized by normal TCR-induced 
activation markers, but are not able to differentiate into 
either Th1, Th2 or TH17 cells. Moreover, they fail to 
express the lineage-specific transcription factors, T-bet, 
Figure 6: Effect of Rapamycin on the expression levels of the genes shared among the mTOR network and the CD4 
migratory phenotype in CD4 T cells, as measured by qRT-PCR in Th17 cells.
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Figure 7: Effect of Rapamycin on the expression levels of the genes shared among the mTOR network and the CD4 
activated phenotype in CD4 T cells, as measured by qRT-PCR in Th17 cells.
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GATA3, and RORγt. Along the same lines, Mtor−/− T 
cells upregulate FOXP3 upon TCR stimulation, even in 
the absence of polarizing cytokines. It is believed that 
in T cells the mTOR pathway antagonizes the signaling 
mediated by SMAD and FOXO, that are involved in the 
induction of FoxP3. Also, upstream receptors, such as 
PDL1 and S1PR1, by activating mTOR, are able to inhibit 
the generation of iTregs. It is likely that mTORC1 and 
mTORC2 exert diverse effects on T cell polarization. 
RHEB deficiency, that leads to loss of mTORC1, 
negatively affects Th1/Th17 differentiation. T cells 
deficient for RHEB show increased activity of SOCS3, 
and the silencing of the latter is associated to a restoration 
of Th1 differentiation. On the other hand, mTORC2 
loss, via deletion of RICTOR, is associated to a reduced 
polarization of T cells toward a Th2 phenotype, without 
affecting the development of Th17 cells.  This effects 
seems to be mediated by both protein kinase C-theta 
(PKCθ) and SOCS5 signaling. 
On the other hand, it has also  been shown that 
blocking mTOR activity by pharmacological intervention 
induces T cell anergy in vitro, likely interfering with 
the transduction of the costimulatory signaling of the 
immunological synapsis (reviewed in [31]). 
Although in our experiments on Th17 cells in vitro, 
we have specifically focused on the modulation of genes 
likely involved in MS development and progression, as 
determined by the in silico analysis, we were not able to 
detect a fully polarization toward the Treg phenotype. 
Indeed, we observed only a moderate upregulation of 
FoxP3, along with a limited downregulation of IL17F, and 
no modulation of other Treg markers, including CD121a, 
IL7R and ARG2 (data not shown).
In the present work, we also wanted to investigate 
the possible involvement of mTOR in the process of 
remyelination, in order to evaluate whether the use of 
drugs targeting the PI3K/Akt/mTOR pathway could exert 
beneficial effects on the CNS lesions of MS patients.
Remyelination is the process by which new myelin 
sheaths are generated around axons in the adult central 
nervous system following injury. Remyelination occurs in 
the MS lesions but becomes progressively inadequate, thus 
causing permanent disability in patients. Remyelination 
occurs in two major steps. The first consists in the 
colonization of lesions by oligodendrocyte progenitor cells 
(OPCs), the second in the differentiation of OPCs into 
myelinating oligodendrocytes that contact demyelinated 
axons to generate functional myelin sheaths [32]. 
Current available data on the involvement of 
mTOR in the myelination process are often discordant. 
Cell-specific loss of Pten, an endogenous inhibitor of 
mTOR, in oligodendrocytes and Schwann cells, promotes 
hypermyelination [33]. Moreover, inhibition of mTOR 
by Rapamycin interferes with the development of 
galactocerebroside positive immature oligodendrocytes in 
purified oligodendrocyte precursor cell (OPC) cultures and 
also reduces the number of myelinating oligodendrocytes 
when OPCs are cocultured with dorsal root ganglia neurons 
[34]. A role for mTOR in oligodendrocyte function has 
been also hypothesized by Flores and collaborators, who 
generated transgenic mice overexpressing a constitutive 
active form of Akt in oligodendrocytes and observed an 
increased amount of myelin produced per oligodendrocyte 
without modification of the oligodendrocyte cell number 
[35]. On the other hand, when Rapamycin is injected in 
an in vivo model of tuberous sclerosis, myelination was 
enhanced [36]. In a similar fashion, Rapamycin improved 
myelination in explant cultures from neuropathic mice by 
activating autophagic mechanisms [37].
Our data show that a significant involvement of the 
mTOR network can be observed only in the early phases 
of oligodendrocyte maturation, i.e. in neonatal OPCs. 
Little or no contribution of mTOR can be observed in the 
maturation process of adult oligodendrocytes from adult 
OPCs, and in the process of remyelination following 
demyelinating injury.
These observation are concordant with the fact that 
in active cortical MS lesion, a significant enrichment 
for the mTOR network can be observed only among the 
downregulated genes.
Overall, our data suggest that targeting the PI3K/
mTOR pathway, although it may not be a useful 
therapeutic approach to promote remyelination in 
MS patients, however it can be exploited to exert 
immunomodulation, preventing/delaying relapses, and to 
treat MS patients in order to slow down the progression 
of disability.
ACKNOWLEDGMENTS AND FUNDING
The research idea was proposed by K.M, F.N. and 
P.F. The experiments were designed and performed by 
S.M., M.S.B. and E.C. The data were analyzed and results 
interpreted by P.B., E.M., M.C.P., S.D.N. and J.A.M.. 
S.M. and P.F. wrote the main manuscript. The revision 
and editing of the manuscript was performed by all 
authors. Part of this work was presented at the 22nd World 
Congress on Advances in Oncology and 20th International 
Symposium on Molecular Medicine, Athens, Greece.
CONFLICTS OF INTEREST
The authors declare no competing financial interests.
REFERENCES
 1.  Giacoppo S, Pollastro F, Grassi G, Bramanti P, Mazzon 
E. Target regulation of PI3K/Akt/mTOR pathway by 
cannabidiol in treatment of experimental multiple sclerosis. 
Fitoterapia. 2017; 116:77–84. https://doi.org/10.1016/j.
fitote.2016.11.010.
Oncotarget8276www.impactjournals.com/oncotarget
 2.  Liu Y, Zhang D, Liu X. mTOR Signaling in T Cell 
Immunity and Autoimmunity. Int Rev Immunol. 2015; 
34:50–66. https://doi.org/10.3109/08830185.2014.933957.
 3.  Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long 
J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, 
Mazzarino MC, Donia M, Fagone P, Malaponte G, et al. 
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR 
pathways in controlling growth and sensitivity to therapy-
implications for cancer and aging. Aging (Albany NY). 
2011; 3:192–222. https://doi.org/10.18632/aging.100296.
 4.  McCubrey JA, Steelman LS, Chappell WH, Abrams SL, 
Franklin RA, Montalto G, Cervello M, Libra M, Candido 
S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, et al. 
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade 
inhibitors: how mutations can result in therapy resistance 
and how to overcome resistance. Oncotarget. 2012; 3:1068–
111. https://doi.org/10.18632/oncotarget.659.
 5.  Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams 
SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone 
P, Malaponte G, Mazzarino MC, Nicoletti F, et al. Ras/
Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: 
Rationale and Importance to Inhibiting These Pathways 
in Human Health. Oncotarget. 2011; 2:135–64. https://doi.
org/10.18632/oncotarget.240.
 6.  Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen 
K. mTOR as a multifunctional therapeutic target in HIV 
infection. Drug Discov Today. 2011; 16:715–21. http://
www.ncbi.nlm.nih.gov/pubmed/21624501.
 7.  Donia M, McCubrey JA, Bendtzen K, Nicoletti F. Potential 
use of rapamycin in HIV infection. Br J Clin Pharmacol. 2010; 
70:784–93. https://doi.org/10.1111/j.1365-2125.2010.03735.x.
 8.  Nicoletti F, Lapenta C, Lamenta C, Donati S, Spada M, 
Ranazzi A, Cacopardo B, Mangano K, Belardelli F, Perno 
C, Aquaro S. Inhibition of human immunodeficiency virus 
(HIV-1) infection in human peripheral blood leucocytes-
SCID reconstituted mice by rapamycin. Clin Exp 
Immunol. 2009; 155:28–34. https://doi.org/10.1111/j.1365-
2249.2008.03780.x.
 9.  Baroja-Mazo A, Revilla-Nuin B, Ramírez P, Pons JA. 
Immunosuppressive potency of mechanistic target of 
rapamycin inhibitors in solid-organ transplantation. World 
J Transplant. 2016; 6:183. https://doi.org/10.5500/wjt.
v6.i1.183.
10.  Bergmann L, Maute L, Guschmann M. Temsirolimus for 
advanced renal cell carcinoma. Expert Rev Anticancer Ther. 
2014; 14:9–21. https://doi.org/10.1586/14737140.2014.864562.
11.  Sasongko TH, Ismail NF, Zabidi-Hussin Z. Rapamycin 
and rapalogs for tuberous sclerosis complex. Cochrane 
Database of Systematic Reviews. 2016; 7:CD011272. 
https://doi.org/10.1002/14651858.CD011272.pub2.
12.  Blair J, Barry R, Moore DJ, Denniston AK. A comprehensive 
review of mTOR-inhibiting pharmacotherapy for the 
treatment of non-infectious uveitis. Curr Pharm Des. 2017; 
23:3005–3014. Available from http://www.ncbi.nlm.nih.
gov/pubmed/28078989.
13.  Ashburn TT, Thor KB. Drug repositioning: identifying 
and developing new uses for existing drugs. Nat Rev 
Drug Discov. 2004; 3:673–83. https://doi.org/10.1038/
nrd1468.
14.  DiMasi JA, Hansen RW, Grabowski HG. The price of 
innovation: new estimates of drug development costs. J 
Health Econ. 2003; 22:151–85. https://doi.org/10.1016/
S0167-6296(02)00126-1.
15.  Chong CR, Sullivan DJ. New uses for old drugs. Nature. 
2007; 448:645–6. https://doi.org/10.1038/448645a.
16.  Chong ZZ. mTOR: A Novel Therapeutic Target for Diseases 
of Multiple Systems. Curr Drug Targets. 2015; 16:1107–32. 
http://www.ncbi.nlm.nih.gov/pubmed/25850623.
17.  Fischer MT, Wimmer I, Hoftberger R, Gerlach S, Haider L, 
Zrzavy T, Hametner S, Mahad D, Binder CJ, Krumbholz M, 
Bauer J, Bradl M, Lassmann H. Disease-specific molecular 
events in cortical multiple sclerosis lesions. Brain. 2013; 
136:1799–815. https://doi.org/10.1093/brain/awt110.
18.  Moyon S, Dubessy AL, Aigrot MS, Trotter M, Huang JK, 
Dauphinot L, Potier MC, Kerninon C, Melik Parsadaniantz 
S, Franklin RJM, Lubetzki C. Demyelination causes 
adult CNS progenitors to revert to an immature state 
and express immune cues that support their migration. 
J Neurosci. 2015; 35:4–20. https://doi.org/10.1523/
JNEUROSCI.0849-14.2015.
19.  Aranami T, Yamamura T. Th17 Cells and Autoimmune 
Encephalomyelitis (EAE/MS). Allergol Int. 2008; 57:115–
20. https://doi.org/10.2332/allergolint.R-07-159.
20.  Martelli AA, Evangelisti C, Chiarini F, McCubrey JA. 
The Phosphatidylinositol 3-kinase/AKT/mTOR signaling 
network as a therapeutic target in acute myelogenous 
leukemia patients. Oncotarget. 2010; 1:89–103. https://doi.
org/10.18632/oncotarget.114.
21.  Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, 
Cappellini A, Ognibene A, McCubrey JA. The emerging role 
of the phosphatidylinositol 3-kinase/Akt/mammalian target 
of rapamycin signaling network in normal myelopoiesis and 
leukemogenesis. Biochim Biophys Acta. 2010; 1803:991–
1002. https://doi.org/10.1016/j.bbamcr.2010.04.005.
22.  Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its 
interactions with the PI3K/AKT/mTOR signalling network. 
Adv Biol Regul. 2017; 65:5–15. https://doi.org/10.1016/j.
jbior.2017.06.003.
23.  Follo MY, Manzoli L, Poli A, McCubrey JA, Cocco L. 
PLC and PI3K/Akt/mTOR signalling in disease and cancer. 
Adv Biol Regul. 2015; 57:10–6. https://doi.org/10.1016/j.
jbior.2014.10.004.
24.  Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, 
Schmidt MH, Murali R. Discrete signaling mechanisms of 
mTORC1 and mTORC2: Connected yet apart in cellular 
and molecular aspects. Adv Biol Regul. 2017; 64:39–48. 
https://doi.org/10.1016/j.jbior.2016.12.001.
25.  Ricciardi MR, Mirabilii S, Licchetta R, Piedimonte M, 
Tafuri A. Targeting the Akt, GSK-3, Bcl-2 axis in acute 
Oncotarget8277www.impactjournals.com/oncotarget
myeloid leukemia. Adv Biol Regul. 2017; 65:36–58. https://
doi.org/10.1016/j.jbior.2017.05.002.
26.  Donia M, Mangano K, Amoroso A, Mazzarino MC, 
Imbesi R, Castrogiovanni P, Coco M, Meroni P, Nicoletti 
F. Treatment with rapamycin ameliorates clinical and 
histological signs of protracted relapsing experimental 
allergic encephalomyelitis in Dark Agouti rats and induces 
expansion of peripheral CD4+CD25+Foxp3+ regulatory 
T cells. J Autoimmun. 2009; 33:135–40. https://doi.
org/10.1016/j.jaut.2009.06.003.
27.  Esposito M, Ruffini F, Bellone M, Gagliani N, Battaglia 
M, Martino G, Furlan R. Rapamycin inhibits relapsing 
experimental autoimmune encephalomyelitis by 
both effector and regulatory T cells modulation. J 
Neuroimmunol. 2010; 220:52–63. https://doi.org/10.1016/j.
jneuroim.2010.01.001.
28.  Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, 
Feinstein DL, Dello Russo C. Rapamycin reduces 
clinical signs and neuropathic pain in a chronic model 
of experimental autoimmune encephalomyelitis. J 
Neuroimmunol. 2012; 243:43–51. https://doi.org/10.1016/j.
jneuroim.2011.12.018.
29.  Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. 
Rapamycin induces feedback activation of Akt signaling 
through an IGF-1R-dependent mechanism. Oncogene. 2007; 
26:1932–40. https://doi.org/doi:10.1038/sj.onc.1209990.
30.  Gamper CJ, Powell JD. All PI3Kinase signaling is not 
mTOR: dissecting mTOR-dependent and independent 
signaling pathways in T cells. Front Immunol. 2012; 3. 
https://doi.org/doi:  10.3389/fimmu.2012.00312.
31.  Chi H. Regulation and function of mTOR signalling in T 
cell fate decision. Nat Rev Immunol. 2012; 12:325–38. 
https://doi.org/10.1038/nri3198.
32.  Chari DM. Remyelination in multiple sclerosis. Int Rev 
Neurobiol. 2007; 79:589–620. https://doi.org/10.1016/
S0074-7742(07)79026-8.
33.  Goebbels S, Oltrogge JH, Kemper R, Heilmann I, Bormuth 
I, Wolfer S, Wichert SP, Möbius W, Liu X, Lappe-Siefke 
C, Rossner MJ, Groszer M, Suter U, et al. Elevated 
phosphatidylinositol 3,4,5-trisphosphate in glia triggers 
cell-autonomous membrane wrapping and myelination. 
J Neurosci. 2010; 30:8953–64. https://doi.org/10.1523/
JNEUROSCI.0219-10.2010.
34.  Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, 
Levison SW, Wood TL. Activation of the Mammalian Target 
of Rapamycin (mTOR) Is Essential for Oligodendrocyte 
Differentiation. J Neurosci. 2009; 29:6367–78. https://doi.
org/10.1523/JNEUROSCI.0234-09.2009.
35.  Flores AI, Narayanan SP, Morse EN, Shick HE, Yin X, Kidd 
G, Avila RL, Kirschner DA, Macklin WB. Constitutively 
Active Akt Induces Enhanced Myelination in the CNS. 
J Neurosci. 2008; 28:7174–83. https://doi.org/10.1523/
JNEUROSCI.0150-08.2008.
36.  Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, 
Kwiatkowski DJ. Response of a neuronal model of tuberous 
sclerosis to mammalian target of rapamycin (mTOR) 
inhibitors: effects on mTORC1 and Akt signaling lead to 
improved survival and function. J Neurosci. 2008; 28:5422–
32. https://doi.org/10.1523/JNEUROSCI.0955-08.2008.
37.  Rangaraju S, Verrier JD, Madorsky I, Nicks J, Dunn WA, 
Notterpek L. Rapamycin activates autophagy and improves 
myelination in explant cultures from neuropathic mice. J 
Neurosci. 2010; 30:11388–97. https://doi.org/10.1523/
JNEUROSCI.1356-10.2010. 
